LONG MINI-FUTURE - GENMAB | Delayed Deutsche Boerse AG 13:01:18 27/06/2024 BST | ||
| 6.98 EUR | +2.80% |
|
| Current month | -22.31% | ||
| 1 month | -23.45% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 27/06/24 | 6.98 | +2.80% |
| 26/06/24 | 6.79 | +1.04% |
| 25/06/24 | 6.72 | -0.30% |
| 24/06/24 | 6.74 | -1.61% |
| 20/06/24 | 6.85 | +6.20% |
Delayed Quote Deutsche Boerse AG
Last update June 27, 2024 at 01:01 pm
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VE93FP |
| ISIN | DE000VE93FP5 |
| Date issued | 17/03/2020 |
| Strike | 1,279 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.88 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 29.19 € |
|---|---|
| Lowest since issue | 1.18 € |
| Spread | 0.02 € |
| Spread % | 0.29% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,791
DKK
Average target price
2,464
DKK
Spread / Average Target
+37.58%
- Stock Market
- Certificates
- Certificat
